Maria L. Morales - Publications

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia

Published: January 23, 2026

Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a-/- murine model.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 12, 2024

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.

Journal: Microbiome

Published: June 11, 2024

miR-146a-/- mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype.

Journal: American journal of hematology

Published: August 18, 2023

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases.

Journal: Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada

Published: July 07, 2023

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.

Journal: Cell reports. Medicine

Published: June 22, 2023

Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses.

Journal: Haematologica

Published: March 07, 2023

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.

Journal: Leukemia

Published: February 07, 2023

Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 20, 2023

Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?

Journal: Cancers

Published: January 14, 2023

High-Throughput CRISPR Screening in Hematological Neoplasms.

Journal: Cancers

Published: June 29, 2022

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.

Journal: Blood advances

Published: May 26, 2022